




# Infographic of the Early Manifest Glaucoma Trial (EMGT)

Valentina Di Croce <sup>1</sup> · Nawani Wickramaratne<sup>1</sup> · Christin Henein <sup>1</sup> · Rashmi G. Mathew<sup>1</sup>

Received: 22 October 2020 / Revised: 29 November 2020 / Accepted: 9 December 2020 / Published online: 11 June 2021  
© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021



**Fig. 1** The Early Manifest Glaucoma Trial (EMGT) showed that early reduction of intraocular pressure in patients newly diagnosed with primary open angle glaucoma using laser trabeculoplasty and topical betaxolol hydrochloride lowered the risk of disease progression. IOP intraocular pressure, NNT number needed to treat, POAG primary open angle glaucoma.

**Reference to original study:** Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10): 1268–1279.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Rashmi G. Mathew  
r.mathew@ucl.ac.uk

<sup>1</sup> UCL Institute of Ophthalmology, London, United Kingdom